Wayne L Furman

Summary

Publications

  1. ncbi request reprint Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study
    Wayne L Furman
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 20:1617-24. 2002
  2. pmc Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 3678, USA
    J Clin Oncol 27:4599-604. 2009
  3. pmc Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Pediatr Blood Cancer 58:372-9. 2012
  4. pmc Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 115:655-64. 2009
  5. pmc Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors
    Fariba Navid
    Departments of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Cancer Res 19:236-46. 2013
  6. pmc Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 115:1765-75. 2009
  7. pmc Avoiding misdiagnosing neuroblastoma as Wilms tumor
    Paxton V Dickson
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 43:1159-63. 2008
  8. doi request reprint Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma
    Atmaram S Pai Panandiker
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 3678, USA
    Pediatr Blood Cancer 60:761-5. 2013
  9. pmc A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Invest New Drugs 30:1660-70. 2012
  10. ncbi request reprint Phase I study of everolimus in pediatric patients with refractory solid tumors
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 25:4806-12. 2007

Collaborators

Detail Information

Publications40

  1. ncbi request reprint Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study
    Wayne L Furman
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 20:1617-24. 2002
    ....
  2. pmc Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 3678, USA
    J Clin Oncol 27:4599-604. 2009
    ..To assess the effect of gefitinib on the pharmacokinetics of IV irinotecan and on the bioavailability of a single oral dose of irinotecan...
  3. pmc Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Pediatr Blood Cancer 58:372-9. 2012
    ..Administration of an oral cephalosporin allowed advancement of the dosage of oral irinotecan. This study investigates whether administration of an oral cephalosporin increases the maximum tolerated dose (MTD) of intravenous irinotecan...
  4. pmc Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 115:655-64. 2009
    ..The combination of a platinating agent and etoposide has induced responses in various pediatric tumors. The study estimated the maximum tolerated dose (MTD) of an oxaliplatin and etoposide regimen in children with recurrent solid tumors...
  5. pmc Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors
    Fariba Navid
    Departments of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Cancer Res 19:236-46. 2013
    ....
  6. pmc Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study
    Lisa M McGregor
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 115:1765-75. 2009
    ..For this report, the authors estimated the maximum tolerated dose (MTD) and investigated the toxicities of oxaliplatin combined with irinotecan in children with refractory solid tumors...
  7. pmc Avoiding misdiagnosing neuroblastoma as Wilms tumor
    Paxton V Dickson
    Department of Surgery, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Surg 43:1159-63. 2008
    ..We reviewed our 20-year experience (1987-2006) treating patients with NBL, focusing on those with an initial diagnosis of WT, to determine presenting features that would have suggested the correct preoperative diagnosis...
  8. doi request reprint Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma
    Atmaram S Pai Panandiker
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 3678, USA
    Pediatr Blood Cancer 60:761-5. 2013
    ..Locoregional failure is a significant concern in patients with high-risk abdominal neuroblastoma (NB) receiving radiotherapy. Locoregional control outcomes were studied in children with NB receiving intensity modulated radiotherapy (IMRT)...
  9. pmc A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA
    Invest New Drugs 30:1660-70. 2012
    ..This Phase II pilot study estimated the rate of response to two courses of intravenous irinotecan plus oral gefitinib in children with untreated high-risk neuroblastoma...
  10. ncbi request reprint Phase I study of everolimus in pediatric patients with refractory solid tumors
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 25:4806-12. 2007
    ....
  11. pmc Factors that distinguish symptoms of most concern to parents from other symptoms of dying children
    Michele Pritchard
    Division of Nursing Research, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pain Symptom Manage 39:627-36. 2010
    ....
  12. ncbi request reprint Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach
    Victor M Santana
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    J Clin Oncol 23:4039-47. 2005
    ..To estimate the response rate and toxicity associated with intravenous topotecan when it is administered on a protracted schedule according to a pharmacokinetically guided dosing approach to treat childhood high-risk neuroblastoma...
  13. pmc Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib
    Trevor McKibbin
    Department of Clinical Pharmacy, University of Tennessee, Memphis, TN, United States
    Eur J Cancer 46:2045-51. 2010
    ..To investigate associations between germline genetic variations in the epidermal growth factor receptor (EGFR) and toxicity in paediatric patients treated with gefitinib...
  14. doi request reprint Disease control intervals in high-risk neuroblastoma
    Victor M Santana
    Department of Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee 38105 2794, USA
    Cancer 112:2796-801. 2008
    ..The intervals of disease control in the patients in the current study with recurrent neuroblastoma were characterized to provide comparison criteria for exploratory studies of new agents...
  15. ncbi request reprint Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience
    Fariba Navid
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 106:1846-56. 2006
    ..Vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide are highly effective against pediatric sarcomas. The authors investigated the feasibility of administering these agents concomitantly within a defined period...
  16. pmc Decision making by parents of children with incurable cancer who opt for enrollment on a phase I trial compared with choosing a do not resuscitate/terminal care option
    Scott H Maurer
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 28:3292-8. 2010
    ....
  17. ncbi request reprint UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan
    Clinton F Stewart
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 25:2594-600. 2007
    ....
  18. pmc Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience
    Jared R Robbins
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Surg 45:678-86. 2010
    ..The purpose of the study was to compare outcomes of pediatric patients with high-risk metastatic neuroblastoma who received radiotherapy (RT) with those of patients who did not...
  19. ncbi request reprint Colorectal carcinoma in childhood and adolescence: a clinicopathologic review
    D Ashley Hill
    Department of Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 25:5808-14. 2007
    ..Pediatric colorectal carcinoma (CRC) is rare, but the available data suggest that it is more likely than adult CRC to be advanced at presentation and to have a poor outcome. We sought to better characterize pediatric CRC...
  20. ncbi request reprint The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience
    Lisa M McGregor
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 104:2837-46. 2005
    ..It remains unclear whether primary tumor resection benefits patients with metastatic neuroblastoma. The authors assessed the impact of extent and timing of resection on outcome in these patients...
  21. ncbi request reprint Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 24:3678-85. 2006
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase inhibitor, depsipeptide, in children with refractory or recurrent solid tumors...
  22. ncbi request reprint Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients
    Burgess B Freeman
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer Invest 24:310-7. 2006
    ..Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous...
  23. ncbi request reprint Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
    ..Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors...
  24. pmc A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors
    Fredric A Hoffer
    Department of Radiological Sciences, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA
    Cancer 115:1328-37. 2009
    ..This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors...
  25. pmc Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 30:2005-12. 2012
    ..Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts. We determined whether recent improved treatment had narrowed the gap in outcome between black and white pediatric patients...
  26. pmc Bereaved parents' perceptions about when their child's cancer-related death would occur
    Michele Pritchard
    Division of Nursing Research, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pain Symptom Manage 38:561-7. 2009
    ..Clinicians can use these descriptions and the associated symptom patterns to help families prepare for their child's last week and last day...
  27. pmc Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data
    M Beth McCarville
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Radiol 42:824-33. 2012
    ..Little information exists regarding pediatric contrast-enhanced US...
  28. ncbi request reprint Tumor recurrence at thoracostomy tube insertion sites: a report of two pediatric cases
    Andrea A Hayes-Jordan
    Department of Surgery, Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Surg 39:1565-7. 2004
    ....
  29. ncbi request reprint Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794l, USA
    J Clin Oncol 24:563-70. 2006
    ....
  30. ncbi request reprint Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Pediatr Hematol Oncol 28:635-41. 2006
    ..The selective expression of MYCN in tumor cells, and the sensitivity of detection of MYCN by RT-PCR noted in this and other studies, supports further evaluation of MYCN as a NB marker for molecular detection of minimal residual disease...
  31. ncbi request reprint Clinical and diagnostic imaging findings predict anesthetic complications in children presenting with malignant mediastinal masses
    Doralina L Anghelescu
    Division of Anesthesiology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Paediatr Anaesth 17:1090-8. 2007
    ..The presence of a mediastinal mass in a child poses significant anesthesia-related risks including death. To optimize outcome clinicians must be able to predict which patients are at highest risk of anesthetic complications...
  32. ncbi request reprint The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma
    Fariba Navid
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 103:780-7. 2005
    ..In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatric patients with Stage III melanoma involving regional lymph nodes...
  33. doi request reprint Cancer-related symptoms most concerning to parents during the last week and last day of their child's life
    Michele Pritchard
    Department of Oncology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    Pediatrics 121:e1301-9. 2008
    ..The purpose of this study was to identify the cancer-related symptoms that most concerned parents during the last days of their child's life and the strategies parents identified as helpful with their child's care...
  34. doi request reprint Stability of sunitinib in oral suspension
    Fariba Navid
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38112, USA
    Ann Pharmacother 42:962-6. 2008
    ..Sunitinib is a novel, oral, multitargeted tyrosine kinase inhibitor with antiangiogenic and antitumor activity. No liquid formulation of sunitinib malate is commercially available for pediatric administration...
  35. ncbi request reprint Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:829-37. 2004
    ..We conducted a phase I trial of the injectable formulation of topotecan given orally once daily for 5 days for 2 consecutive weeks (qd x 5 x 2) in pediatric patients with refractory solid tumors...
  36. ncbi request reprint Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy
    Andrew M Davidoff
    Department of Surgery, St Jude Children s Research Hospital and the University of Tennessee, Memphis, TN 38105, USA
    Pediatr Blood Cancer 44:158-62. 2005
    ..The purpose of this study was to evaluate resectability of the primary tumor and regional disease, as determined radiographically, in children with high-risk neuroblastoma during neoadjuvant chemotherapy...
  37. ncbi request reprint End-of-life care preferences of pediatric patients with cancer
    Pamela S Hinds
    Division of Nursing Research and Patient Care Services, Department of Hematology Oncology, Palliative and End of Life Care Task Force, and Ethics Committee, St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 23:9146-54. 2005
    ..We identified the preferences of children and adolescents with advanced cancer about their end-of-life care and the factors that influenced their decisions...
  38. ncbi request reprint Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening
    Robert P Sanders
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Blood Cancer 47:851-4. 2006
    ..We review the clinical and molecular aspects of the relationship between hepatoblastoma and FAP, and the implications for diagnostic testing and cancer screening in affected patients...
  39. ncbi request reprint Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial
    Lars M Wagner
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 22:1886-93. 2004
    ..To evaluate the efficacy of recombinant erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) in reducing blood transfusion requirements and stimulating hematopoiesis in children with high-risk neuroblastoma...
  40. ncbi request reprint Typhlitis in childhood cancer
    M Beth McCarville
    Division of Diagnostic Imaging, Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA jude org
    Cancer 104:380-7. 2005
    ..The authors investigated the demographic, clinical, and imaging (ultrasonography and computed tomography [CT] scans) variables related to the diagnosis, risk, and outcome of typhlitis...